<819A C8A438E5989C C89C85F FB4985E939D8D87312E706466>
|
|
|
- よしお しのしま
- 7 years ago
- Views:
Transcription
1 obgytokai135@cs-oto.com 1-1
2
3 obgytokai135@cs-oto.com 1-1
4 Plus One 1 2 1
5 :20 11:40 1 3F :50 12: :30 12: :00 13: :15 15: F 2 1 4F 1 1 4F 2 1 4F :15 18: :00 11:30 13:30 15:00 1 4F :10 18: :30 20: :00 13: : F 2 1 4F 3 B1F 1 1 4F 2 1 4F 1 1 4F
6 TEL: JR JR 19 JR JR m ,
7 4F EV EV Plus One F 2 3 2F 4 5 4F EV F 3 4 EV18 4 B1F EV F F F EV18 4 N
8 1 2 Plus One 14F 14F 14F F F F F F F 143 3B1F 4F Plus One F F
9 3F 4F 1F Plus One Plus One F 1F B1F 3 B1F
10 1 4F :00 17:30 11: :00 14:30 5, F :00 18: :00 16:00 1 3F :00 18: :00 14: TEL F135
11 PC Windows7 30 USB PC PC Windows Power Point 2007/2010/2013 OS MS MS USB a. wmv b. Power Point c. USB PC Macintosh PC Windows Windows USB PC Mini D-Sub15pin Macintosh WindowsPC AC USB PC 10
12 F 1 4F 1 4F F Plus One 13F :00 11:50-12:30 11:20-11:40 13:00 13:00-13:05 12:30-12:50 13:05-14:10 13:05-14: :00 14:10-15:15 14:10-15: :00 16:00 17:00 18:00 15:30-16:15 16:15-17: :15-15:30 17:10-18:10 17:10-18: :15-18: :00-18:00 19:00 18:30 20:30 3B1F
13 F 1 4F 1 4F F Plus One 8:40-9:45 8:40-9: :00 9:45-10:50 9:45-10: :00-11:30 10:00 10:50-11: :10-15:25 10:50-11:50 12:00-13:00 12:00-13:00 13:10-14: :10-14:10 14:10-15: Bevacizumab :30-15: D 4 5 GE 9:00-14:30 11:00 12:00 13:00 14: :00 14F 14F : :00 17:30 11:00 18: :00 14:30 8:00 16:00 16:00
14
15
16 13:00 13:05 13:05 14: CPA 7MEA 14:10 15:15 8 ART Residual Ovary Syndrome MRI AT 14 1 JA 15:30 17: :10 18:10 ES1
17 11:50 12:30 12:30 12:50 13:05 14:10 15 TRY Step1 16 Laparoscopic sacrocolpopexy:lsc V.S :10 15: TTP SLE Reversible Cerebral Vasoconstriction Syndrome DIC 15:15 15:30 17:10 18:10 ES2
18 15:15 18:
19 8:40 9:45 29 QOL :45 10: CD TAE osteopathia striata with cranial sclerosis 1 42 AV PSTT 1 10:50 11: :00 13:00 LS1-1 G2 LS1-2 Staging Laparotomy en bloc
20 13:10 14: :10 15: rec-fsh PCOS PCOSPCOM :25
21 8:40 9: TTTS 54 Posterior reversible encephalopathy syndrome :45 10:50 58( B1 ) :50 11:50 65 Bevacizumab 4 66 G-CSF IABO 1
22 12:00 13:00 LS2 Bevacizumab 13:10 14:10 71 SLE FGR Massive perivillous fibrin deposition 2 76 preeclampsia gestational hypertension 14:10 15: TCR D-CT 81 Edwardsiella tarda pseudo-meigs syndrome bizarre leiomyoma 10:00 11:30/13:30 15: D 4 5 GE
23
24 Intentional Design ID OSCE
25 ( ) WHO 8
26
27
28 NIPT MRI CT (CVD) NO ADMA GnRHa CVD (DNG) DNG (EP) EP E P E EP norethysterone(net) drospirenone(drsp) EE+DRSP EE+NET TG HDL-C EP DNG
29 QOL QOL
30
31
32
33 %( 3-5%) 1% 85% ( 77.1 ) 7 Paget (2 ) PS IB1 47 IB2 12 IIA cm 0-7cm 0=CIS % ,16,11,11,12,18,16, mL mL 5 8.1% RCC 2,2,4,4, day5 9 day7 53 day5 105 day % day % 1 1.6%day105 IB1 47 IB % under diagnosis % over diagnosis 6.4% IB % under diagnosis1 8.3% over diagnosis7 58.3% IIA % %
34 3 4 VEGF CF stage C TC CA U/ml 3 + CT Stage A 6 CT 1 CT PET/CT IgG4 IgG4
35 Gy cm cm ( ) 160cm 71kg BMI CT
36 MEA Hb 1.5 MEA 2 RCC 12 Hb 13.3 GnRHa adenomyosis leiomyoma MEA Residual Ovary Syndrome(ROS) ROS (ART) AIH IVF-ET 46 MRI ( mm) ROS LEP mm cm CA U/ml MRI 1 ROS GnRHa 2 ART ROS
37 (TLH) TLH ( 8 ) () () 120g 100g () g water disection water disection (p 0.05) R-ASRM %(9 5 ) ovarian reserve AMH
38 :Laparoscopic Sacrocolpopexy(LSC):Pelvic Organ Prolapse(POP) POP 2014 LSC POP 11 LSC (DM-LSC) (SM-LSC) 65.5 (56 77 ) DM-LSC 230 ( ) SM-LSC 178 ( ) 20mL(0 150mL) 1 1 DM-LSC SM-LSC POP LSC LSC POP LSC MRI CT MRI 15cm 800ml benign cystic tumor 2 27 MRI 9cm 350ml serous cystadenoma MRI
39 13 14 JA 26 AT 26 AIH AT 14 AT / follow up 26 3 CT AT FDP D g 2 CT 14 (AT- ) AT- (DVT) (PE) DVT AT VTE AT- 35.0% AT- 9.6mg/dl protein S protein C LAC CL AT- type1 AT- PE informed consent Ca AT- IUGR 36 VTE AT gAp8 9 AT- DVT
40 TRY Step Step 1 Step 2 Step 3 Step Step 1 Tr 1Tr 2 Tr 3 Tr 4Tr 5 Tr 6 6 overlap underlap Step Tr Tr Tr Tr Tr Tr Step1 0 Step 2 TRY LSC Aa1.0,Ba1.0,C1.0 + POP-Qstage LSC ml Aa-1.0,Ba0.0,C1.0 + POP-Qstage LSC ml POP-Qstage POP
41 17 18 V.S MRI CA125 CA19-9 MRI margin hernia sac endometriosis DIC 32 A 15 B 17 BMI A 26 B 21 C 5 BMI A / B 24.9 / / /1.6 A 54 B 36 C /8 54 p= A B 5 A /B :0 /1 :1 /0 :0 /1 :0 /0 :1 /0 :2 /0 :0 /0 :0 /1 7.6 /7.2 N.S.
42 (Hyperreactioluteinalis, HL) HCG HL cm 7cm 7 ( 5cm ) 1 8cm 3 10cm (VTE) v3.0 JCOG/JSCO,,,, ( )g 2017( )g VTE 24
43 21 22 (hemophagocytic syndrome HPS),, LDH,,. PHS 1. 27,1 1, 32 2,33 3,. 33 6,,.,, CRP,,AT-,.CT,,.3.,,HPS., HPS. 7,,,,.,,, CT,,,HPS. 19, HPS.,,, LDH,HPS. (Extremely Emergent Cesarean Section :EECS) EECS EECS EECS EECS EECS (8-35 ) 22.1 ( ) 21 ( ) (85 ) EECS 30 EECS 24 EECS
44 CTG g Apgar3/ IUFD HELLP TTP AKI ADAMTS13 ADAMTS13 TTP ADAMTS13 SLE 2 ADAMTS13 SLE 38 0 TTP SLE
45 (16 46 ) 27 (17%) 85 (53%) 4 15 (9%) 21 (13%) (14%) 16 (11%) 34 (21%) 10 (6%) 1 15 (9%) 13 (8%) RCVS Reversible Cerebral Vasoconstriction Syndrome % PRES Posterior Reversible Encephalopathy Syndrome 9-63% RCVS RCVS MRA 4 3 MRI PRES PRES 3 2 RCVS RCVS RCVS
46 / /3889 1% IVF-ET 35 G3P1 IVF-ET 8 40mmHg 1280ml g g disseminated intravascular coagulation syndrome: DIC DIC recombinant human trombomodulin: rhtm DIC DIC rhtm DIC rhtm rhtm n= rhtm DIC n=37 rhtm DIC DIC DIC 2 D-dimer DIC DIC rhtm rhtm 2 p<0.01 D-dimer p=0.01 rhtm 2 DIC p=0.01 DIC
47 QOL (CART) QOL CART CART IL CART CART CART % 62.1% IL % 8 CART 2 PR CART 4 PS CART QOL 5 CART Papanicolaou class 3a 3 3b 13.9% % % % % % % % 75 G1:35 G2:16 G3: MMMT TAM
48 A FIGO Kaplan-Mayer (91.8%) FIGO I 221 (69.9%) II 16 (5.1%) III 64 (20.3%) IV 15 (4.8%) 5 I 95.9%(Ia 99% Ib 85.5%) II 85.9% III 64.1% IV 26.8% typei( G1,G2) 257 (81 ) 5 90typeII 59 5 II
49 CT PET / L CRP 2.5mg/L CA U/mL QuantiFERON TB PCR CT PET Langhans MRI mL g Apgar score 8/9 1 /5 DIC PIH
50 G4P cm g AP9/10 ph g 19 17BP69/46mmHg HR A SI=2 CT Hb5.9 PLT FDP>300 ICU 2 0:00 UAE g RCC40U FFP45U PC40U Zn-CP1<1.6pmol/mL STN 13.8U/mL 2 33 G2P cm variable deceleration g AP3/8 ph g BP98/49mmHg HR131 SI= SBP60mmHg 4300g 1 32 B SI=2 Hb2.1 PLT5000 FDP>109 Fib ICU g RCC38U FFP26U PC30U SI IUC IVR
51 37 CD CD36 type I CD36 CD36 CD CD36 CD mL 2418g Apgar score 9-9 NICU 6.7 / l / l 50ml / l 16 1 CD36 CD36 1 CD36 TAE (transcatheter arterial embolization) g S.I.(shock index)2.0 Hb9.2 CT extravasation TAE extravasation RCC10 FFP g TAE 3 TAE DIC 1
52 (ABPM) (PIH) PIH PE (GH) ABPM /80mmHg 160/110mmHg PE GH WHT PE (- ) / 10% dipper -10% non-dipper riser Cosinar PE 29 GH20 (WHT) PE /97 7 GH /91 8 WHT 116 5/69 3mmHg PE 23 GH 11 Dipper PE 4 3 GH 5 0WHT 6 Non-dipper PE 10 (6) GH8 (3) WHT 8 riser PE15 (14) GH9 (8) PE 12 (11) GH9(6) WHT PE 8 (6) GH4(3) WHT 0 WHT GH GH GH PE GH (CAOS) (CLD) g Apgar0/1/9(1 /5 /10 ) 1 CLD CLD 164 (DCH)+ (CAM)3 + CAOS CAOS CAOS CAOS
53 41 42 osteopathia striata with cranial sclerosis( OSCS) ( ) D-CT OSCS 37 BPD11.3 (+6.7SD) g Apgar score 6/7(1 /5 ) CT OSCS Placental-site trophoblastic tumor PSTT PSTT XX HCG:45.2 IU/l 4.5 cm CT angiography 6 cm A-V 2 cm CT HCG 2 cm HCG PSTT
54 Uterine Artery Embolization; UAE UAE Level A UAE UAE UAE UAE 12 UAE GnRH agonist UAE UAE DIC 1 UAE GnRH agonist 8 UAE 3 GnRH agonist UAE UAE PCOS OHSS rec-fsh F rec-fsh IU 20 hcg5000iu 18 4 hcg BMI, hcg BMI %(14/27) 74.6%(44/59) hcg 25.4%(15/59) 59.3%(35/59) OHSS / BMI %(14/30) hcg 53.3%(16/30) 26.7%(8/30) rec-fsh
55 , ml % % 2 23% 17%
56 % 81.8% 76.7% 63.6% p= % 54.5% p=0.46 (cesarean scar pregnancy: CSP), (cesarean section: CS) 0.15%, CS 6.1%., (uterine artery embolization: UAE), UAE. UAE CSP 4. 1: 41, G3P1(CS 1),. 10 4, hcg 11,700 miu/ml. (MTX),. 2 39, G5P1(CS 1),,. 6 1 ( 1 ), hcg 9,450 miu/ml. 2 MTX, 9 MTX. 3 37, G2P2(CS 1),. 7 ( 1 ), hcg 74,500 miu/ml. 2 MTX, 3DCTA, 9 MTX. hcg, 29,. 4 30, P1(CS 1). 7 4 ( 1 ), hcg 54,700 miu/ml. MTX, 8 MTX, 13 3DCTA, 17.,. CSP 4,.,, DCTA,,, UAE.
57 PCOS 5 8 PCOS PCOS PCOM PCOS PCOM PCOS 60 PCOM 59 BMI 75gOGTT 0 2 AMH (T) PCOS S,PCOM M S 32.4 M OGTT mg/dl 140~200mg/dl (IGT) S 15.2 M 11.8 AMH S 11.7 ng/ml M 7.5 ng/ml HOMA-R 1.6 IGT S 12.5 M 9.3 BMI25 IGT S 21,G BMI25 S 10.8 G 7.5 M S IGT BMI HOMA-R 10 IGT IGT GDM S M BMI IGT MRI g 17cm 2-4 3cm MRI
58 PIH PIH PIH PIH BNP LVEF 55% / E/E 15 BNP 100 pg/ml 106 PIH 25 PIH PIH p=0.68 LVEF 55% 3 2.9% PIH 1 4.0% p=0.78 E/E % PIH % p=0.02 BNP 100 pg/ml % PIH % p<0.01 BNP PIH PIH 1 PIH 1,2 1, ( ) P (22-35 ) 38 (28-40 ) I 15 (56%) IIa 2 (7%) II2 (7%) III 1 (4%) IV 1 (4%) V 6 (22%) 5 (18%) III 5 (18%) I 1 II 2 III (11%) 4 (14%) 1 (4%) 1 (4%) (P=0.001) III
59 53 TTTS 54 TTTS FLP 12 2 FLP70 MD MD 24 66/68 (97%), 108/136 (79%) 24/136 (17%) , 7 (TAPS) Posterior reversible encephalopathy syndrome PRES 97.9 MRI PRES PRES 11 PRES / mmhg / mmhg PRES MRI PRES PRES MRI
60 /87mmHg 105/ 59.8 X 8.3ml/ EF 22 IVC 21mm ICU IABP Carperitide (VTE) VTE VTE VTE VTE BMI VTE % % VTE VTE P< BMI % / % 5/6 83% VTE 20 VTE VTE VTE
61 MRI MRI 1 10% 5% 3% A B 10,000 1 A B 19 B (29 33 ) ASC-H 16 0 ASC-US Adenocarcinoma MRI/ 17 3 Adenosquamous carcinoma(pt1b1 19mm 6mm) 19 2 (B2) g
62 G4P ASC-US DAV (30 42) 4 IB1 6 IB2 1 IIB 1 IB2 IIB (25 31) (1 85)
63 CT ER CK7 CK20 cdx2 TC S 84 endometriosis associated intestinal tumors(eaits) BPD 20 1 B A A 26 1 AFI AFI PGE PGF g Ap:1/8 1
64 m % GnRH 1 CT 10 GnRH GnRH GnRH 2 D
65 65 Bevacizumab FIGOstageI 17% stage II/III 89% KM-CART Bevacizumab(BEV) VEGF 3 AUREILA trial BEV 4 BEV7.5mg/kg/4w pt2bn1m ml BEV pt3cn1m BEV BEV pt3cnxm ml BEV pt3cn1m ml BEV 2 BEV CART Bevacizumab G-CSF CRP CT WBC 22600/ Hb 7.9g/dl CRP 16.9mg/dl MRI CT 815g Hb 6.7g/dl G-CSF G-CSF G-CSF
66 TLS tumor lysis syndrome TLS Stage c TLS TLS TLS TLS 1 2 CA mm 24 38mm CA CA MRI 25mm 5 CT 2 Serous adenocarcinoma Peritoneal dissemination, pt4,pn0,pm1 TC 2
67 mm 10-25mm % % (p =0.09) 15% 10 IABO(intra-aortic balloon occlusion) IABO 1 39 IVF-ET 38 1 shock index 1.2 IABO shock index 0.6 shock index 2.0 IABO shock index IABO
68 71 72 SLE Interstitial pneumonia: IP) SLE IP prednisolone(psl)10mg/ IP PSL 20mg/ 29 CT IP 31 CT g Apgar score 9 (1 )/10 5 PSL20mg/ SLE IP (single umbilical artery: SUA) 2 (fused umbilical artery: FUA) g 6 / g 5 / SUA FUA 3.1 SUA /3 FUA FUA FUA SUA 3
69 NST 1512g Apgar score NST reassuring pattern 34 NST 2614g Apgar score NST reassuring pattern 1 NST reassuring pattern g Apgar score ITP ITP / L ml 1.5 ITP ITP ml ml ITP ml 2.1 ITP
70 Massive perivillous fibrin deposition(mpfd) FGR MPFD FGR 35 5 PIH 1390g MPFD 22 FGR g FGR g MPFD FGR 36 growth stop 1754g 6 MPFD MPFD MPFD MPFD MPFD (PIH) PIH 2009 preeclampsia (PE) gestational hypertension (GH) PIH 58 PE 32 GH ml (mg)/h 30 1ml/h / (SBP) %I ( mmhg) PE 8 GH 2 II ( mmhg) PE 21 GH 14 III (180 mmhg ) PE 3 GH 10 PIH JSSHP PE 1ml/h I 2 II 8 III 1 2ml/h I 4 II 10 III 1 3ml/h I 2 II 3 III 1 GH 1ml/h I 2 II 11 III 4 2ml/h I 0 II 3 III 5 3ml/h I 0 II 0 III 1 PE 1ml/h % 2ml/h % 3ml/h % GH 1ml/h % 2ml/h % PE 1ml/h 2ml/h 2/3 / GH 1ml/h 2/3
71 hair ball MRI 4cm Inflammatory myofibroblastic tumor FISH ALK MRI 19.1% % 90 ADL WBC13800/ l CRP12.13mg/dl PCT11.67ng/ml CT MRI DIC ICU 2 3 ICU 13 Micromonas micros
72 79 80 TCR TCR TCR 12 Hb in-out mm g 63mm 1 100ml Hb g/dl Hb g/dl in-out ml leiomyoma10 3 endometrial polyp endometrial polyp1 adenomyomatous polyp Hb4.3g/dl Hb 1 1.8g/dl TCR TCR postpartum hemorrhage: PPH 3D-CT 3D-CTA PPH 3D-CTA 3D-CTA PPH PPH 20 PPH TAE PPH TAE PPH 3D-CTA
73 81 82 Edwardsiella tarda(et) 40-50% WBC22800/ l CRP45mg/dl BP59/37 MEPM MRI JCS -1 WBC30500/ l CRP12.2mg/dl BP107/70 HR65 BT37.1 ICU MEPM CLDM ET CRP WBC MEPM CLDM 14 ET ,X 50% 45,X Y gonadoblastoma dysgerminoma 14 45,X[29]/46,X,?Y[1].ish idic(y)(q11.2) 2.19ng/ml gonadoblastoma MRI 15 mixed gonadal dysgenesis
74 vicryl PDS 10Fr. 3-0 vicryl A 3-0 PDS B A 3M 2 CMZ1g 1 2 B 2 6 CMZ1g 3 A B BMI A 45 8 B 44 1 P 0.05 BMI Meigs true- Meigs syndrome pseudo-meigs syndrome pseudo-meigs syndrome bizarre leiomyoma 49 2 pseudo-meigs syndrome CT 14 CA U/ml bizarre leiomyoma 5 pseudo-meigs syndrome bizarre leiomyoma
75
76 LS1-1. G G2 Oozing QOL NTT ()
77 LS1-2. Staging Laparotomy en bloc Staging Laparotomy en bloc en bloc Staging Laparotomy en bloc 4 Staging Laparotomy KCOG ASCO member
78 LS2. Bevacizumab Bevacizumab(BEV) VEGF VEGF VEGFR BEV (vascular endothelial growth factor VEGF ) IgG1 VEGF VEGF VEGF VEGF driven cancer 97 vascular endothelial growth factor VEGF ligand BEV GOG218 ICON7 OCEANS AURELIA
79 ES1. ( () 8 Free radical ( )
80 ES2. HPV ASCUS HPV N
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
11 第25回がん学会一般演題一覧（第3会場）
1) 2) 1) 2) KTSND 2 200 KTSND KTSND 2014 4 CD56 Chromogranin Ki67 70% CT T2N4M0stage IVa /(egfr 55ml/min Cre 1.05mg/dl)/ PR 12 2015 4 CT 6 62 20XX 6 CTMRI 5 7 10 DIC methotrexatemtx /5-FU DIC score ALP
本文／一般演題＿吉田
184 quality of lifeqol mmhg Hb gdl CA Uml Niveau Hb Hb gdl RCC CT MRI T 185 CT A B MRI A:T B:T Douglas red spot S ml RCC 186 A B mg CAUml S MRI A B 187 188 S mg Sampson JA. Intestinal adenomas of endometriosis
‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01
2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation
QOL 02 QOL QOL UI AI EAThoracotomy TTThoracoscopy TS QOL EA type-c y score UI 3 AI 8 School score QOL score 12
54 1 2018 2 4-1 OK-432 1 15 14 15 US CT MRI 17 cm 0.16 g/kg/day OK-432 3 1 ke 2 2 ke 3 1 1,150 ml 13 US OK-432 4-2 TJ-28 TJ-28 2003 3 2017 6 250 TJ-28 44 16 28 TJ-28 7 2 46 8.5 2 2 9 34 79.1 10 23.3 34
178 44 2 179 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 6 O-001 O-002 O-003 O-004 O-005 O-006 O-007 O-008
1 2 3 4 5 1 2 176 177 3 4 é 5 6 1 2 3 4 5 6 44 2 178 44 2 179 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 6 O-001 O-002 O-003 O-004 O-005 O-006 O-007 O-008 180 44 2 181 1 2 3 4 5 6 7 1 2 3 4 5 O-009 O-010 O-011 1 O-012
: 1 : 50 mm : RCC 4 FFP ml 2. 1 : MRI : T2 6 cm flow void : Gd T1 UAE UAE 4 57
34, 25-30, 2014 0.05 5.3% UAE TCR MTX 2013 7 1 11 31 4 1 36 1 1 2011 10 39 1 5 1 50 mm 1, MRI MRI T1 T2 flow void Gd T1 2, 50 UAE TCR 50 mm 700 ml 3 10 1 26 1. 1 : 1 : 50 mm : 3 2 36 4 2 2 2 13 49 RCC
第 14 回血管病理研究会 日時 : 平成 20 年 10 月 10 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ) CRP MPO-ANCA 125IU/l CT mpa
第 4 回血管病理研究会 日時 : 平成 20 年 0 月 0 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ). 67 2008 CRP MPO-ANCA 25IU/l 009 2 CT mpa GCA PSL 50 mg CRP MPO-ANCA mpa GCA 4 mpa ovarlap 2 TLR 2 2. 対象 方法
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
卵巣癌の治療
K-net:2008.7.17 85 90 8 10 20 (FIGO) a (FIGO) b (FIGO) c (FIGO) a (FIGO) b (FIGO) c (FIGO) (FIGO) (FIGO) Risk factors Preventive factors Risk factors 35 PCO, Preventive factors? Relative risk
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
untitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
- 9 91, (2006)
Case study level Ma Management of testicular cancer - 9 91, 10 0.7 2.4 (2006) 20 30 20 20-40 AFP -hcg -hcg AFP TNM T ptx pt0 ptis pt1 / pt2 / pt3 / pt4 / N NX N0 N1 2cm 1 2cm N2 2cm 5cm 1 5cm N3 5cm TNM
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
ISSN Endo Relief AFP AFP AFP. ng/ml CT cm CA. U/ml AFP L. FIGO c AFP AFP DC AFP. ng/ml AFP L. CT cm MRI. cm cm CA. U/ml CA - CEA PIVKA- CT Key words Alfha-fetoprotein, Surface epithelial malignant ovarian
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6
Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6
051
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
C VECS C F M kg A E W kg I A R. R. Gkg MGD MGD MGD MGD SPKMGD MGD MGD SPK SPK MGD MMP MMP MMP kg mmhg Intrascleral prosthesis : ISPISP ISP ISP ISP ISP ISP ISP ISP ISP mm mm ISP mm min mm min ISP mm min
72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4
![=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4](/thumbs/91/107033392.jpg "=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4")
1 1 1 1.1 1.1.1 3 : 0: + : +0 : : } 40 40 40 = 3 35 35 (38 )? +0+7 30 35-0+0 38 38 +30 5 30 30 +20 16 16 1. [ ] 2. 3. 4. + = etc 1.1.2 Ru 1 2 1.2 1.2.1 =PAS.. =.. =.... 1% 01% ] 1.2.2 = = = = 4 (A/A 2
untitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
溶血性尿毒症症候群 ver 最終.pptx
Hemolytic uremic syndrome(hus) ver0130525 (HUS), Stx VT 3 3 1. ( Hb10g/dl ) 2. ( 10 /µl ) 3. ( 97.5 ) 1.5 ) (HUS) D+HUS D-HUS(aHUS) HUS ahus ( 6 HUS ( ) HUS HUS ahus O-157 9-30 HUS 15 80 5 5 10 2-3 (O-157
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
世 界 体 外 受 精 会 議 記 念 賞 候 補 演 題 プログラム 世 界 体 外 受 精 会 議 記 念 賞 候 補 演 題 ( 基 礎 ) 8 8 ( )9:00 10:10 2 2F -1 R-spondin2-2 1 2 IVF 1 1 1 1 1 2 1-3 A ES H2A 1 2 3 4 1 2 1 1 1,3 4 3-4 C-type natriuretic peptide(cnp)
indd
18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,
日本呼吸器学会雑誌第47巻第6号
Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons
54 6 2018 10 pp. 1173-1193 doi: 10.11164/jjsps.54.6_1173 1173 34 The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 30 2018 10 27 10-1 3-6-2 HP URL https://psjm2018.com/ 34 PSJM2018
41-6_50回中国地方会Pr6N__HP掲載用.indd
2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.
* 1 6 ( ) 20 GOT GPT ( ) 59 3 CT F D T3 *
-259 3101 * 1 6 () 20 GOTGPT 3 155169 2 5 () 59 3 CT 129 59 F D T3 * -- 428 - -259 3101 * 3 5 4 6 () 159 NOS () 158 159 R 4U T3 500ml 2ml 2g 100ml 25mg PL 162 152 152 37 1630 92mg/dl PL 3g/ 3 300mg/ 3
全国循環器撮影研究会 HP講座No
HP No.6 4 HP No.6 4 NTT 1. 1936 1953 Seldinger Seldinger 1956 Odman X Interventional Radiology IVR 1967 Margulis 1964 Dotter 2. 2.1 IVR CT MR IVR 2.2-1 - HP No.6 4 2.3 feeding artery parasitic supply increased
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
Microsoft Word - 第２回海外勤務健康管理抄録の表紙他.doc
第 2 回 海 外 勤 務 者 健 康 管 理 研 修 会 平 成 19 年 3 月 10 日 ( 土 ) (14 時 ~17 時 ) ( 独 ) 労 働 者 健 康 福 祉 機 構 大 阪 労 災 病 院 管 理 棟 3F 大 ホール 591-8025 大 阪 府 堺 市 北 区 長 曾 根 町 1179 番 地 の3 共 催 ( 社 ) 大 阪 府 医 師 会 ( 社 ) 日 本 産 業 衛 生
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
untitled
PGF 17 6 1 11 1 12 1 2 21 2 22 2 23 3 1 3 1 3 2 3 3 3 4 3 5 4 6 4 2 4 1 4 2 4 3 4 4 4 5 5 3 5 1 5 2 5 5 5 5 4 5 1 5 2 5 3 6 5 6 1 6 2 6 6 6 24 7 1 7 1 7 2 7 3 7 4 8 2 8 1 8 2 8 3 9 4 9 5 9 6 9 3 9 1 9
マニュアル第４版表紙PDF
5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.
3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: jiao@nacos.com 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26
25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (
JHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
mrna Zc3h12a IL-6
mrna Zc3h12a IL-6 IgG4 The 4th East Asian Group of Rheumatology (EAGOR2011) S3PE CaMK EBM PubMed NHK TBS European Thyroid Journal Nature, Lancet msv ICRP msv msv msv WHO COE sirna M M M VS VS VS
<B54CB5684E31A4E9C0CBA4E5AA6BC160BEE3B27AA544A5552E706466>
N1 2 3 1 16 17 18 19 20 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 4 2 38 39 40 41 42 44 45 46 47 48 50 51 52 53 54 55 56 57 58 59 60 61 5 3 62 63 64 65 66 68 69 70 70 72 74 75 76 77 78 80 81 82 83
Microsoft Word - 第302回プログラム最終版（H ）.pdf
HP 24 10 15 24 10 24 302 374 24 11 10 9 00 16 30 20 A 1-2-27 TEL 06-6949-5151 602-8566 465 TEL 075-251-5620 FAX 075-251-5840 E-mail rad@koto.kpu-m.ac.jp http://www.jrs-kansai.jp/ PC 1 Macintosh PC Windows
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
provider_020524_2.PDF
1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24
051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
日本消化器外科学会雑誌第39巻第10号
WBC Table1 Laboratoryfindings 9,000/μl RBC 396 10 4 /μl Hb 9.8 g/dl adrenaline 46 pg/ml (
救急車同乗実習レポート 総括
14 9 1 9 10 10 19:00 23:00 52 1 6.5 40 CT X CT Ope 15 /min BP 100/70mmHg HR 96 /min O U m 60 25/min BP 140/80mmHg HR 55 O Spo 98 BP 172/68mmHg O 30 15 /min BP 100/60mmHg HR 80 /min BS O O CO 30 40 JCS
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
LMC-CA144U2
LMC-CA144U2_V01 USB 2.0 Memory Card READER LMC-CA144U2 ... 1... 4... 5... 5... 6... 6... 11... 13 USB 2.0... 20 Macintosh... 21... 21 Mac OS X... 21 Mac OS... 25... 28 Macintosh... 31 Windows... 33...
ito.dvi
1 2 1006 214 542 160 120 160 1 1916 49 1710 55 1716 1 2 1995 1 2 3 4 2 3 1950 1973 1969 1989 1 4 3 3.1 3.1.1 1989 2 3.1.2 214 542 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
頸部リンパ節腫張 のコピー.pptx
17 1cm LMP General : BP110/70 HR60 RR16 T37.2 Eye Oral Neck ( cm Lungs Heart Abd Skin : cm Hb g/dl Ht Plt. /µl WBC /µl Seg Lym Mono AT-Ly Baso Na meq/l K meq/l Cl meq/ L Ca BUN mg/dl Cr mg/ dl GOT IU/L
GL改訂_野原班DST.indd
Quality of Life QOL HRQL Circulation Journal Vol. 71, Suppl. IV, 2007 1 HRQL ASO ASO ASO ASO 2 Circulation Journal Vol. 71, Suppl. IV, 2007 evidence based medicine a a b A B C,, A Quality of LifeQOL HDL
59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1
59 20 : 50 : 2005 9 : 2006 1 : 2006 4 : :2 / :20 / 25 GTP 2006 1 4/28 5/35/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3:78 / :156/78mmHg 1 0.3g 1 30-49 Hb9.5g/dL 7 /mm 3 - Cr1.6mg/dL CRP1.84 mg/dl
日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
一般演題
世界体外受精会議記念賞 候補演題プログラム 世界体外受精会議記念賞候補演題 ( 基礎 ) 7 26 9:10 10:10 1 B -1-2 -3-4 CXCL5-CXCR2 1 2 3 1,2 3 2 1,2 1 2 Poor responder C-type natriuretic peptide (CNP) 1 2 1,2 1 2 1 2 Resistant ovary syndrome (ROS)
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
Gifu University Hospital Cancer Center 1 2 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center 3 4 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center
untitled
30803040 1015 1 2 3 4 5 6 60 7 8 [ ] [] [ ] / 9 10 [] [] [] / () 11 12 61 13 Borg 14 15 16 mm mm 17 () BMI 200mg/dl 18 Anderson 200mmHg 120mmHg 40mmHg 20mmHg 62 AED 19 20 () 21 22 23 24 63 25 26 27 28
03J_sources.key
Radiation Detection & Measurement (1) (2) (3) (4)1 MeV ( ) 10 9 m 10 7 m 10 10 m < 10 18 m X 10 15 m 10 15 m ......... (isotope)...... (isotone)......... (isobar) 1 1 1 0 1 2 1 2 3 99.985% 0.015% ~0% E
...J......1803.QX
5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299
PowerPoint Presentation
Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
21 1 503604705 MRI CT 1 3 MRIMRS 5 5 5 5 5 6 7 8 17 1 17 2 17 3 17 4 18 5 19 21 1 23 2 1 27 3 2 48 4 3 88 5 105 6 110 7 118 MRS MRS ATP 312CT 65 60 1 2 1 1 1 2 1 2 2 X CT MRS 3 36657269 MRIMRS 1.5TMRSymphony
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
第4回クッキーテスト研究会研究報告集（PDF）
2007 H19.8 2007 5 26 () 2 3 7 9 12 14 15 18 25 29 1 2 () (g g kcal) mg/dl.mg/dl ( U/mlhr).(mg/dl*U/ml) 50.2 158.6cm 70.7kg 28.1kg/ 92.5cm ( ) () ( ) (.(.-.)g/ml.(-.) g/ml ((MS) MS MS cm 2 MS () 3 4 122/74
Mobile Base Station RTR-500MBS-A / Web Storage - RTR-500MBS LED / Copyright T&D Corporation. All rights reserved. 2017. 07 16504810016 8 -------------------------------------- 3 -----------------------------------------------
B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13:
![B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13:](/thumbs/94/118646867.jpg "B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13:")
B. 41 II: ;; 4 B [] S 1 S S 1 S.1 O S 1 S 1.13 P 3 P 5 7 P.1:.13: 4 4.14 C d A B x l l d C B 1 l.14: AB A 1 B 0 AB 0 O OP = x P l AP BP AB AP BP 1 (.4)(.5) x l x sin = p l + x x l (.4)(.5) m d A x P O
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
ALTIA_BS_2017.pdf
AUTOMOTIVE SERVICE EQUIPMENT 2017-2018 BEST SELECTION NEW PRODUCTS 1937-2017 80 NEW PRODUCTS 2017 ALTIA! OPEN MIND DPF!! DPF!! DPF DPF DPF!! 20!! 3! EE5000-0000 AC 100 V 50/60Hz 25W W500D520H950mm 75 kg
抄録_46回中国地方会37-6_責.indd
46 22 9 11 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN 146 62 146 123 HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density
からだにeヘルシーレシピ 高血圧
We b e 3,5 00 7day 1. 2. & 3. 1 C O N T E N T S 2.6 0 1 0 5 0 7 1 0 9 17 2 2 2 3 CHECK&POINT! 2 5 24 1 2 7 e 2 9 e 3 1 webe 3 3 6 12 18 24 6 16 16g 111 1 6 1 2010 2010 18 20 3,970 18 1 400 2.6 01 02 140mmHg
GL_尾崎班_D.indd
Circulation Journal Vol. 72, Suppl. IV, 2008 1319 Churg-Strauss ANCA ANCA 1 1 1320 Circulation Journal Vol. 72, Suppl. IV, 2008 ANCA 1 ANCA ANCA 2 Circulation Journal Vol. 72, Suppl. IV, 2008 1321 2 2
ρ(= kg m 3 ), g h P 0 C () [1] 1.3 SI Pa hpa h 100 ( : 100 ) 1m 2 1N 1Pa 1N 1kg 1m s 2 Pa hpa mb hpa 1mm 1mmHg hpa 1mmHg =
![ρ(= kg m 3 ), g h P 0 C () [1] 1.3 SI Pa hpa h 100 ( : 100 ) 1m 2 1N 1Pa 1N 1kg 1m s 2 Pa hpa mb hpa 1mm 1mmHg hpa 1mmHg =](/thumbs/91/105600732.jpg "ρ(= kg m 3 ), g h P 0 C () [1] 1.3 SI Pa hpa h 100 ( : 100 ) 1m 2 1N 1Pa 1N 1kg 1m s 2 Pa hpa mb hpa 1mm 1mmHg hpa 1mmHg =")
I. 2006.6.10 () 1 (Fortan mercury barometer) 1.1 (Evangelista orricelli) 1643 760mm 760mm ( 1) (P=0) P 760mm 1: 1.2 P, h, ρ g P 0 = P S P S h M M = ρhs Mg = ρghs P S = ρghs, P = ρgh (1) 1 ρ(= 13.5951 10
METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,
2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002
16 9 Paula TFC BMI PSL hydroxysteroid dehydrogenase (11 -HSD) modulator ( prereceptor mod
Glucocorticoid-Induced Bone Disease (Clinical Practice) NEJM, July 7, 2011 Robert S. Weinstein, M.D. NEJM July 7 2011 Clinical Practice Glucocorticoid-Induced Bone Disease Arcansas Robert S. Weinstein,
2005年基準 国内企業物価指数（DCGPI） 調査対象商品一覧
HP http://www.boj.or.jp/type/exp/stat/pi/excgpi03.htm 1 2 2 250ml 1000ml 80g 90g 4 130g 500g Q10 500ml 1.5l 190g 250g 2l 500ml 2l 50ml 100ml 720ml 350ml 500ml 350ml 500ml 350ml 1.8l 2l 20304080 15d 70d
J-STAGE 原 著 要旨 5 reversible cerebral vasoconstriction syndrome RCVS posterior reversible encephalopathy syndrome PRES RCVS PRES Key
原 著 1 2 3 2 要旨 5 reversible cerebral vasoconstriction syndrome RCVS posterior reversible encephalopathy syndrome PRES RCVS PRES Key words: pregnancy-associated stroke, cortical subarachnoid hemorrhage,